Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.
about
Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysisTuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data.[Medication treatment of rheumatoid arthritis with a history of malignancy. Epidemiological data].Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry.Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.APLAR rheumatoid arthritis treatment recommendations.Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain SetRisk factors for infection following total joint arthroplasty in rheumatoid arthritis.Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases.Pharmacology of intra-articular triamcinolone.Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort.Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management.Safety of tumor necrosis factor inhibitor therapy in patients with a prior malignancy.Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty.Prophylaxis for latent tuberculosis infection prior to anti–tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis.2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management.[Perioperative handling of immunosuppressive therapy].Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.The landscape of comparative effectiveness research in rheumatology.Comparison of latent tuberculosis infection screening strategies before tumor necrosis factor inhibitor treatment in inflammatory arthritis: IGRA-alone versus combination of TST and IGRA.
P2860
Q26786213-77E8E78C-AA48-476C-A925-10DE130F12D7Q30799235-0E0EA990-DD20-42E4-98DD-F16C6C1CB7EFQ31036951-E6DC38F1-135E-4AD2-8E76-34DD96364CDFQ31152756-EFD6FB8A-D5A2-4836-93AD-AB90D577533EQ34520662-BB24C5AB-0590-4E7B-92BF-88FE911BEF72Q35762912-940F73EE-766E-436C-A932-173530E308DFQ36947638-56DF6C91-ECD1-40ED-A11C-F7F52EF4E739Q37486363-6B7FB6F3-41C0-46E5-BA63-E7125B2C8440Q37654774-97CB121F-D490-4B06-B63E-BE0E3F2FD971Q38169909-E76F4802-9357-4A1A-8EA9-0C1687505EDBQ38211488-1DC3F5CB-6D52-48C3-A44D-084D8607BFC8Q38401295-589DB335-1093-46A2-BB54-03933FF94438Q38458992-ACD877D3-5C80-4C04-BB7F-816ACF5B2FC0Q39811930-F1FACF05-E45C-4818-9113-FB33AB6416B6Q40081220-101CA1D2-8A45-48CA-819F-CFBACF067F66Q40355795-441BD2C9-99A8-4BFE-8266-539239BB6C2FQ44381410-CA618D9F-C2FB-4F11-B3A4-B12EE6570278Q48089791-C520A9C8-0A32-4D2E-BD55-055F1A38A4B1Q49508046-630A9EF8-57D2-45EF-BBE3-E41B2DF1D09BQ49630842-E4BABAFD-BB92-4344-B686-713B59DEF064Q49821178-0AC24F42-B5C7-48F7-9848-E8E6691573A5Q50098797-6ECCAF23-9410-4596-B80C-EBDB618A6A53Q50098937-34CC3FB4-80AC-43E7-B059-4E252102C7D0Q53126847-078DAFA5-7297-465F-9BFC-16EEEB11DE0AQ55717140-BBA8892E-7EE1-4F3F-92B3-F74547D5FEE2
P2860
Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Canadian Rheumatology Associat ...... eumatic drugs: part II safety.
@en
type
label
Canadian Rheumatology Associat ...... eumatic drugs: part II safety.
@en
prefLabel
Canadian Rheumatology Associat ...... eumatic drugs: part II safety.
@en
P2093
P356
P1476
Canadian Rheumatology Associat ...... eumatic drugs: part II safety.
@en
P2093
Anne Dooley
Boulos Haraoui
Canadian Rheumatology Association
Carter Thorne
Claire Bombardier
Dianne P Mosher
Glen S Hazlewood
James Pencharz
Janet E Pope
Jean Légaré
P304
P356
10.3899/JRHEUM.120165
P407
P577
2012-06-15T00:00:00Z